Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global
innovator in drug-delivery platforms, on Thursday provided a strategic update from
the company’s CEO Chris Bunka. Among other highlights, the update includes a
brief recap of achievements from 2019 and an outlook for the new year. “One
objective for the company during 2020 is to dramatically alter our capital
markets strategy. During the last six months Lexaria has met with a number of
Wall Street investment banking firms as we devise our long-term capital markets
strategy. Lexaria expects to pursue a strategy during 2020 to qualify for
listing on a nationally-recognized US exchange, allowing a dramatically larger
audience of investors to consider Lexaria’s attributes and opening a path to
increased quantity and quality of strategic opportunities,” Lexaria Bioscience
CEO Chris Bunka stated in the update.
To view the full press release, visit http://ibn.fm/vmdoT
About Lexaria Bioscience Corp.
Lexaria Bioscience is a global innovator in drug-delivery
platforms. The company’s patented DehydraTECH drug-delivery technology changes
the way active pharmaceutical ingredients enter the bloodstream, promoting
healthier ingestion methods, lower overall dosing and higher effectiveness for
lipophilic active molecules. DehydraTECH increases bioabsorption, reduces time
of onset and masks unwanted tastes for orally administered bioactive molecules
including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs
(“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to
multiple companies in the cannabis industry for use in cannabinoid beverages,
edibles and oral products, as well as to a world-leading tobacco producer for
the development of smokeless, oral-based nicotine products. Lexaria operates a
licensed, in-house research laboratory and holds a robust intellectual property
portfolio with 16 patents granted and over 60 patents pending worldwide. For
more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to established
industry leaders, gaining valuable experience and the expertise necessary to
determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
